- Home
- LOOP vs TLPH Comparison
LOOP vs TLPH Comparison
Compare LOOP & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOOP | TLPH |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.2M | 42.3M |
| IPO Year | 2010 | 2010 |
Fundamental Metrics
Financial Performance| Metric | LOOP | TLPH |
|---|---|---|
| Price | $0.90 | $1.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 81.5K | ★ 273.1K |
| Earning Date | 05-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,889,000.00 | $2,151,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $174.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7016.99 | N/A |
| 52 Week Low | $0.71 | $0.38 |
| 52 Week High | $1.99 | $1.57 |
Technical Indicators
Market Signals| Indicator | LOOP | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 41.87 | 64.07 |
| Support Level | $0.90 | $1.01 |
| Resistance Level | $1.42 | $1.13 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 58.03 | 78.58 |
Price Performance
Historical ComparisonAbout LOOP Loop Industries Inc.
Loop Industries Inc is a technology company whose mission is to accelerate the world's shift toward sustainable PET plastic and polyester fiber and away from dependence on fossil fuels. Loop Industries owns patented and proprietary technology that depolymerizes no and low-value waste PET plastic and polyester fiber, including plastic bottles, packaging, and textiles such as carpets and clothing, into its base building block monomers, DMT and MEG.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.